Accelvecs
Accellvecs Inc. specializes in innovative cancer immunotherapy technologies, including the development and provision of the Syn・Bek (シン・ベック) treatment, which utilizes the patient's own tumor cells to induce tumor-specific immunity. The company is engaged in advanced medical support, licensing of its proprietary technologies, and conducting clinical research to improve cancer treatment outcomes.
Industries
Nr. of Employees
small (1-50)
Products
Autologous tumor-cell vector product for immunotherapy
A processed autologous cell product prepared from a patient's tumor cells by internalizing an NKT-activating compound, irradiating to inactivate cells, and formulated for patient administration or cryopreservation to induce tumor-antigen specific immunity.
GMP-grade NKT cell-activating compound (alpha-galactosylceramide)
Supply of GMP-compliant alpha-galactosylceramide intended for clinical use as an NKT cell activator in human studies and in processing of autologous cell products.
Autologous tumor-cell vector product for immunotherapy
A processed autologous cell product prepared from a patient's tumor cells by internalizing an NKT-activating compound, irradiating to inactivate cells, and formulated for patient administration or cryopreservation to induce tumor-antigen specific immunity.
GMP-grade NKT cell-activating compound (alpha-galactosylceramide)
Supply of GMP-compliant alpha-galactosylceramide intended for clinical use as an NKT cell activator in human studies and in processing of autologous cell products.
Services
Licensing of the autologous tumor-cell vector processing technology and treatment method to medical institutions.
Multi-parameter flow cytometry analysis with 4-laser configuration; options for customer-supplied or vendor-procured antibodies and rapid (next-day) reporting.
ELISA-based cytokine quantification services with next-day reporting option; kits can be supplied by the customer or procured by the provider.
Licensing of the autologous tumor-cell vector processing technology and treatment method to medical institutions.
Multi-parameter flow cytometry analysis with 4-laser configuration; options for customer-supplied or vendor-procured antibodies and rapid (next-day) reporting.
ELISA-based cytokine quantification services with next-day reporting option; kits can be supplied by the customer or procured by the provider.
Expertise Areas
- Autologous cell therapy manufacturing
- Cancer immunotherapy development
- Ex vivo cell culture and processing
- Clinical research and investigator-initiated trials
Key Technologies
- Autologous tumor-cell vector therapy
- Ex vivo short-term cell culture (48–72 h)
- NKT cell activation via alpha-galactosylceramide
- Dendritic cell antigen presentation / neoantigen induction
News & Updates
Yasuyuki Ishii, President & CEO, presented clinical research results on Dec. 9, 2023.
Yasuyuki Ishii, President & CEO, spoke at the event on October 5, 2022.
Accellvecs was recognized as a venture originating from Tokyo Institute of Technology on June 28, 2022.
Received patent rights for a treatment using three existing pharmaceuticals, with clinical trial results showing over 7 years survival in pancreatic cancer.
An article about Yasuyuki Ishii's pollen allergy vaccine was published on December 19, 2024.
Accellvecs was recognized as a venture originating from Tokyo Institute of Technology on June 28, 2022.
Yasuyuki Ishii, President & CEO, presented clinical research results on Dec. 9, 2023.
Yasuyuki Ishii, President & CEO, spoke at the event on October 5, 2022.
Accellvecs was recognized as a venture originating from Tokyo Institute of Technology on June 28, 2022.
Received patent rights for a treatment using three existing pharmaceuticals, with clinical trial results showing over 7 years survival in pancreatic cancer.
An article about Yasuyuki Ishii's pollen allergy vaccine was published on December 19, 2024.
Accellvecs was recognized as a venture originating from Tokyo Institute of Technology on June 28, 2022.